• New opioid-alternative raises $3.25 million for Phase I trials firstwordpharma
    January 13, 2019
    AmacaThera, a Toronto-based company commercializing hydrogel-based drug delivery platforms, has already raised $3.25 million (CAD) in seed financing from Sprout BioVentures, Viva Biotech, and Grey Sky Venture Partners and welcomes additional investors.
PharmaSources Customer Service